Navigation Links
Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial
Date:6/16/2008

ny dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please visit the company's website at http://www.exelixis.com.

Disclaimer

Participation by Dr. Ball and Dr. Nelkin in the development of this product as members of the Clinical Steering Committee does not constitute endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.

Forward-Looking Statements

This press release contains forward-looking statements, including without limitation statements related to: the timing of the initiation and size of clinical trials for XL184; the future development and potential efficacy of XL184; and our strategy to advance compounds and expand into broader commercial markets. Words such as "plan," "expect," "will," "may" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon our current plans, assumptions, beliefs and expectations. Forward-looking statements involve risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the potential failure of XL184 and our other compounds to demonstrate safety and efficacy in clinical
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Exelixis Announces June 19 Webcast of Presentation at the William Blair 28th Annual Growth Stock Conference
2. Exelixis Receives $150 Million Funding Commitment From Deerfield Management
3. Exelixis Announces June 5 Webcast of Conference Call Regarding Its $150 Million Funding Commitment from Deerfield Management
4. Exelixis Announces June 10 Webcast of Presentation at the Goldman Sachs 29th Annual Global Healthcare Conference
5. REMINDER: Exelixis Will Webcast Its June 2 Investor and Analyst Briefing at ASCO
6. Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing
7. Exelixis Announces May 13 Webcast of Presentation at the Bank of America Health Care Conference
8. Exelixis Announces May 6 Webcast of Its First Quarter 2008 Financial Results and Business Update Conference Call
9. Exelixis Announces April 30 Webcast of Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
10. Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting
11. Option to Develop Exelixis Compound Exercised By Genentech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... September 30, 2014.  Biorem,s complete 2014 third quarter financial statements and ... Financial Summary:Three-months ended September 30, , Nine-months ended ... , 2014 , 2013 , 2014 ... 5,281 , 6,715 , 14,476 Gross profit ...
(Date:11/18/2014)... 2014 Athena Signature Series: Turning Cancer ‘Off’ ... Emerson, a professor in the Regulatory Biology Laboratory at the ... discovery points to an “off switch” for drug resistance in ... her local research is making a global impact in the ... then join host Cheryl K. Goodman, CEO of Social Global ...
(Date:11/18/2014)... Array Architects is proud of a 30-year ... nation's hospitals and health systems. It is a niche ... careers to the advancement of both the healthcare and ... field, Laura Silvoy has been chosen to share her ... Conference. , Laura will present her Process Simulation ...
(Date:11/17/2014)... The new METTLER TOLEDO White Paper ... challenges of becoming the first calibration laboratory in ... weights in the microgram range. National Metrology Institutes ... scientists involved in nanotechnology applications will benefit from ... calibration of weights in the range of 0.05 ...
Breaking Biology Technology:Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3Array Healthcare Simulation Expert Slated to Speak at Winter Simulation Conference 2New White Paper on Microgram Weights Describes How to Achieve Traceable Measurement Down to 0.05 Milligrams 2
... Inc. (NASDAQ: NBIX ) today announced its financial results ... the third quarter of 2011, the Company reported net income of ... net income of $3.3 million, or $0.06 per fully diluted share ... ended September 30, 2011, the Company reported a net income of ...
... I: High Blood Pressure , aka Hypertension ... expensive, and mostly ineffective.   Fortunately , ... by natural methods that are both effective, inexpensive, and risk free. ... can help reduce   Chronic Heart/Cardiovascular Disease patients, ...
... Oct. 31, 2011 iBio, Inc. (NYSE ... issuance from the United States Patent and Trademark Office ... Genes in Plants," that further extends iBio,s patent coverage ... technology owned by iBio was developed by scientists at ...
Cached Biology Technology:Neurocrine Biosciences Reports Third Quarter 2011 Results 2Neurocrine Biosciences Reports Third Quarter 2011 Results 3Neurocrine Biosciences Reports Third Quarter 2011 Results 4Neurocrine Biosciences Reports Third Quarter 2011 Results 5Neurocrine Biosciences Reports Third Quarter 2011 Results 6Neurocrine Biosciences Reports Third Quarter 2011 Results 7Neurocrine Biosciences Reports Third Quarter 2011 Results 8Drug-Free BLOOD PRESSURE Control & Medical "Take-Away" Treatment are Potential Win-Win Solutions in Health Care 2iBio Announces New US Patent for iBioLaunch™ Technology 2iBio Announces New US Patent for iBioLaunch™ Technology 3
(Date:11/4/2014)... majority of Madagascar,s 101 species of lemurs are threatened ... the rainforests they call home. A new study by ... have on rainforest tree populations, which raises concerns about ... region,s rich biodiversity. , A large proportion of trees ... Lemurs in turn disperse the seeds of their fruit ...
(Date:11/3/2014)... , Nov. 3, 2014 Research and ... "Cell Therapy - Technologies, Markets and Companies" to ... cell therapy technologies and methods, which have already started to ... stem cell transplantation is replacing the old fashioned bone marrow ... Cell therapy is bound to become a part of medical ...
(Date:11/3/2014)... Nov. 3, 2014  NeuroSigma ® , Inc. ... sciences company focused on commercialization of its non-invasive ... the treatment of neurological and neuropsychiatric disorders, announced ... has issued a Notice of Allowance for Mexican ... co-owned by NeuroSigma and the Regents of the ...
Breaking Biology News(10 mins):Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... DCMay 28, 2008A 2008 American Society for Microbiology (ASM) ... to Marvin Whiteley, Assistant Professor, Molecular Genetics and Microbiology, ... Laboratories, the Merck Irving S. Sigal Memorial Award is ... instrumental in the early discovery of therapies to treat ...
... German . The sense of smell might ... fish or even mammals. This is the main conclusion of ... and her colleagues. The sense of smell in birds was, ... studies have shown that some bird species use their sense ...
... "Leatherback Turtle" you might think the sea turtles could stand ... them, and for more than a hundred million years, they ... of leatherbacks in the eastern Pacific Ocean has plummeted by ... many species that migrate across a vast ocean, pinpointing all ...
Cached Biology News:Do birds have a good sense of smell? 2Leatherback turtles' newly discovered migration route may be roadmap to salvation 2Leatherback turtles' newly discovered migration route may be roadmap to salvation 3Leatherback turtles' newly discovered migration route may be roadmap to salvation 4Leatherback turtles' newly discovered migration route may be roadmap to salvation 5Leatherback turtles' newly discovered migration route may be roadmap to salvation 6
Request Info...
... 5B15-5B-11E. Immunogen: Synthetic peptide derived from ... protein. Specificity: Specific for the ... Western blots it identifies the target band ... (positive controls: deglycosylated secreted media from primary ...
Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
Prepared with distilled water. Yeast extract solution is autolyzed at 150 g/L....
Biology Products: